

# Marie-JosÃ© Kersten

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6656335/publications.pdf>

Version: 2024-02-01

119  
papers

4,018  
citations

186209

28  
h-index

138417

58  
g-index

122  
all docs

122  
docs citations

122  
times ranked

4736  
citing authors

#	ARTICLE	IF	CITATIONS
1	Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2022, 386, 640-654.	13.9	586
2	Effects and moderators of exercise on quality of life and physical function in patients with cancer: An individual patient data meta-analysis of 34 RCTs. <i>Cancer Treatment Reviews</i> , 2017, 52, 91-104.	3.4	398
3	Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). <i>Haematologica</i> , 2020, 105, 297-316.	1.7	230
4	Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2021, 22, 1403-1415.	5.1	222
5	Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study. <i>Lancet Haematology</i> , the, 2020, 7, e112-e121.	2.2	119
6	Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome. <i>Haematologica</i> , 2017, 102, 43-51.	1.7	112
7	Efficacy and safety of <sc>CD19</sc>-directed <sc>CAR</sc> cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the <sc>JULIET</sc>, <sc>ZUMA</sc>, and <sc>TRANSCEND</sc> trials. <i>American Journal of Hematology</i> , 2021, 96, 1295-1312.	2.0	107
8	Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia. <i>Lancet Haematology</i> , the, 2020, 7, e827-e837.	2.2	96
9	Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL. <i>Blood Advances</i> , 2020, 4, 560-572.	2.5	88
10	Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study. <i>Journal of Clinical Oncology</i> , 2023, 41, 555-567.	0.8	82
11	Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy. <i>Blood</i> , 2015, 125, 2306-2309.	0.6	79
12	Carboxy Terminal Variants of Epstein-Barr Virus-Encoded Latent Membrane Protein 1 during Long-Term Human Immunodeficiency Virus Infection: Reliable Markers for Individual Strain Identification. <i>Journal of Infectious Diseases</i> , 1999, 179, 240-244.	1.9	74
13	Targeting Exercise Interventions to Patients With Cancer in Need: An Individual Patient Data Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1190-1200.	3.0	72
14	Dual TOR/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia. <i>Blood</i> , 2016, 128, 574-583.	0.6	69
15	High prevalence of MYD88 and CD79B mutations in intravascular large B-cell lymphoma. <i>Blood</i> , 2018, 131, 2086-2089.	0.6	69
16	Epstein-Barr Virus-Positive Posttransplant Lymphoproliferative Disease After Solid Organ Transplantation. <i>Transplantation Direct</i> , 2016, 2, e48.	0.8	68
17	Randomized controlled trial on the effects of a supervised high intensity exercise program in patients with a hematologic malignancy treated with autologous stem cell transplantation: Results from the EXIST study. <i>PLoS ONE</i> , 2017, 12, e0181313.	1.1	64
18	Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma. <i>Blood</i> , 2015, 125, 449-456.	0.6	60

#	ARTICLE	IF	CITATIONS
19	Investigation and management of IgM and Waldenström-associated peripheral neuropathies: recommendations from the IWWM consensus panel. <i>British Journal of Haematology</i> , 2017, 176, 728-742.	1.2	58
20	Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study. <i>Haematologica</i> , 2021, 106, 1129-1137.	1.7	57
21	MYD88 mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavorable prognosis. <i>Haematologica</i> , 2020, 105, 424-434.	1.7	55
22	Fatigue, anxiety, depression and quality of life in kidney transplant recipients, haemodialysis patients, patients with a haematological malignancy and healthy controls. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 833-838.	0.4	52
23	Moderators of Exercise Effects on Cancer-related Fatigue: A Meta-analysis of Individual Patient Data. <i>Medicine and Science in Sports and Exercise</i> , 2020, 52, 303-314.	0.2	50
24	MYD88 in the driver's seat of B-cell lymphomagenesis: from molecular mechanisms to clinical implications. <i>Haematologica</i> , 2019, 104, 2337-2348.	1.7	48
25	Psychometric properties of two physical activity questionnaires, the AQuAA and the PASE, in cancer patients. <i>BMC Medical Research Methodology</i> , 2011, 11, 30.	1.4	47
26	Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial. <i>Lancet Haematology</i> , 2018, 5, e170-e180.	2.2	44
27	Prognostic relevance of CD138 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium. <i>Haematologica</i> , 2017, 102, 1413-1423.	1.7	39
28	Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high-dose methotrexate, and DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study. <i>Hematological Oncology</i> , 2017, 35, 497-503.	0.8	36
29	Tailoring the amount of treatment information to cancer patients and survivors preferences: Effects on patient-reported outcomes. <i>Patient Education and Counseling</i> , 2020, 103, 514-520.	1.0	31
30	Ibrutinib and idelalisib target B cell receptor- but not CXCL12/CXCR4-controlled integrin-mediated adhesion in Waldenström macroglobulinemia. <i>Haematologica</i> , 2016, 101, e111-e115.	1.7	30
31	Chimeric Antigen Receptor Cell Therapy. <i>HemaSphere</i> , 2018, 2, e18.	1.2	30
32	Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trial. <i>Haematologica</i> , 2020, 105, 2805-2812.	1.7	30
33	Immune checkpoint inhibitor treatment and atherosclerotic cardiovascular disease: an emerging clinical problem. <i>Journal of Internal Medicine</i> , 2021, 291, e002916.		29
34	Sustained Disease Control for Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: An Updated Analysis of Juliet, a Global Pivotal Phase 2 Trial of Tisagenlecleucel. <i>Blood</i> , 2018, 132, 1684-1684.	0.6	28
35	Bortezomib Induction and Maintenance in Patients with Newly Diagnosed Multiple Myeloma: Long-Term Follow-up of the HOVON-65/GMMG-HD4 Trial. <i>Blood</i> , 2015, 126, 27-27.	0.6	28
36	Bortezomib-based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trial. <i>Haematologica</i> , 2019, 104, 2274-2282.	1.7	27

#	ARTICLE	IF	CITATIONS
37	Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: The HOVON/LLPC Transplant BRaVE study. <i>Haematologica</i> , 2019, 104, e151-e153.	1.7	27
38	CD19-directed CAR T-cell therapy in B-cell NHL. <i>Current Opinion in Oncology</i> , 2020, 32, 408-417.	1.1	26
39	Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial. <i>Lancet Haematology</i> , 2018, 5, e479-e492.	2.2	25
40	Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients in the Juliet Trial. <i>Blood</i> , 2019, 134, 4103-4103.	0.6	24
41	High Rates of Minimal Residual Disease-Negative (MRD <sup>-</sup> ) Complete Responses (CR) in Adult and Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL) Treated With KTE-C19 (Anti-CD19 Chimeric Antigen Receptor [CAR] T Cells): Preliminary Results of the ZUMA-3 and ZUMA-4 Trials. <i>Blood</i> , 2016, 128, 2803-2803.	0.6	24
42	CXCL13 levels are elevated in patients with Waldenström macroglobulinemia, and are predictive of major response to ibrutinib. <i>Haematologica</i> , 2017, 102, e452-e455.	1.7	22
43	Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia: Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 40-51.	0.8	22
44	Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma. <i>Blood Advances</i> , 2021, 5, 5128-5139.	2.5	22
45	Developing a digital communication training tool on information-provision in oncology: uncovering learning needs and training preferences. <i>BMC Medical Education</i> , 2018, 18, 220.	1.0	21
46	The Impact of Semiautomatic Segmentation Methods on Metabolic Tumor Volume, Intensity, and Dissemination Radiomics in <sup>18</sup> F-FDG PET Scans of Patients with Classical Hodgkin Lymphoma. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1424-1430.	2.8	20
47	Final results of a phase 1b study of the safety and efficacy of the PI3K <sup>γ</sup> inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies. <i>Blood Cancer Journal</i> , 2018, 8, 16.	2.8	19
48	Precision medicine in diffuse large B-cell lymphoma: hitting the target. <i>Haematologica</i> , 2015, 100, 989-93.	1.7	19
49	Physical activity in patients with cancer: self-report versus accelerometer assessments. <i>Supportive Care in Cancer</i> , 2020, 28, 3701-3709.	1.0	18
50	KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Results of the Phase 2 ZUMA-2 Study. <i>Blood</i> , 2019, 134, 754-754.	0.6	18
51	Efficacy and Safety of Tisagenlecleucel in Adult Patients with Relapsed/Refractory Follicular Lymphoma: Interim Analysis of the Phase 2 Elara Trial. <i>Blood</i> , 2020, 136, 1-3.	0.6	18
52	ZUMA-7: A phase 3 randomized trial of axicabtagene ciloleucel (Axi-Cel) versus standard-of-care (SOC) therapy in patients with relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL). <i>Journal of Clinical Oncology</i> , 2018, 36, TPS7585-TPS7585.	0.8	18
53	Validation and Refinement of Prediction Models to Estimate Exercise Capacity in Cancer Survivors Using the Steep Ramp Test. <i>Archives of Physical Medicine and Rehabilitation</i> , 2017, 98, 2167-2173.	0.5	15
54	Correlation of Bridging and Lymphodepleting Chemotherapy with Clinical Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Tisagenlecleucel. <i>Blood</i> , 2019, 134, 2883-2883.	0.6	15

#	ARTICLE	IF	CITATIONS
55	Bortezomib Maintenance Therapy after Induction with R-CHOP, ARA-C and Autologous Stem Cell Transplantation in Newly Diagnosed MCL Patients, Results of a Multicenter Phase II HOVON Study. <i>Blood</i> , 2015, 126, 339-339.	0.6	15
56	Provider caring and structuring treatment information to improve cancer patientsâ€™ recall: Does it help?. <i>Patient Education and Counseling</i> , 2020, 103, 55-62.	1.0	14
57	<sc>WhiMSICAL</sc>: A global WaldenstrÃ¶m's Macroglobulinemia patientâ€™derived data registry capturing treatment and quality of life outcomes. <i>American Journal of Hematology</i> , 2021, 96, E218-E222.	2.0	12
58	Health-related physical fitness in patients with multiple myeloma or lymphoma recently treated with autologous stem cell transplantation. <i>Journal of Science and Medicine in Sport</i> , 2017, 20, 116-122.	0.6	11
59	The Successful Return-To-Work Questionnaire for Cancer Survivors (I-RTW_CS): Development, Validity and Reproducibility. <i>Patient</i> , 2020, 13, 567-582.	1.1	11
60	Primary therapy and relative survival in classical Hodgkin lymphoma: a nationwide population-based study in the Netherlands, 1989â€“2017. <i>Leukemia</i> , 2021, 35, 494-505.	3.3	11
61	Frequent mutated <i>B2M</i>, <i>EZH2</i>, <i>IRF8</i>, and <i>TNFRSF14</i> in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype. <i>Blood Advances</i> , 2021, 5, 3760-3775.	2.5	11
62	Acalabrutinib in patients (pts) with WaldenstrÃ¶m macroglobulinemia (WM).. <i>Journal of Clinical Oncology</i> , 2018, 36, 7501-7501.	0.8	11
63	Reduced relapse rate in upfront tandem autologous/reduced-intensity allogeneic transplantation in multiple myeloma only results in borderline non-significant prolongation of progression-free but not overall survival. <i>Haematologica</i> , 2015, 100, e508-e510.	1.7	10
64	Clinicopathological characteristics of T-cell non-Hodgkin lymphoma arising in patients with immunodeficiencies: a single-center case series of 25 patients and a review of the literature. <i>Haematologica</i> , 2018, 103, 486-496.	1.7	9
65	Tisagenlecleucel Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study. <i>Blood</i> , 2021, 138, LBA-6-LBA-6.	0.6	9
66	Rituximabâ€™<sc>PECC</sc> induction followed by <sup>90</sup>Yâ€™ibritumomab tiuxetan consolidation in relapsed or refractory <sc>DLBCL</sc> patients who are ineligible for or have failed <sc>ASCT</sc>: results from a phase <sc>II HOVON</sc> study. <i>British Journal of Haematology</i> , 2019, 187, 347-355.	1.2	8
67	Stage-specific trends in primary therapy and survival in follicular lymphoma: a nationwide population-based analysis in the Netherlands, 1989â€“2016. <i>Leukemia</i> , 2021, 35, 1683-1695.	3.3	8
68	Successful Treatment of MYC rearrangement Positive Large B Cell Lymphoma Patients with R-CHOP21 Plus Lenalidomide: Results of a Multicenter Phase II HOVON Trial. <i>Blood</i> , 2018, 132, 786-786.	0.6	8
69	Impact of Tisagenlecleucel Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Attributes on Clinical Outcomes in Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL). <i>Blood</i> , 2019, 134, 242-242.	0.6	8
70	SAR245409 Monotherapy In Relapsed/Refractory Follicular Lymphoma: Preliminary Results From The Phase II ARD12130 Study. <i>Blood</i> , 2013, 122, 86-86.	0.6	8
71	Efficacy of Tisagenlecleucel in Adult Patients (Pts) with High-Risk Relapsed/Refractory Follicular Lymphoma (r/r FL): Subgroup Analysis of the Phase II Elara Study. <i>Blood</i> , 2021, 138, 131-131.	0.6	8
72	Serum neurofilament light chain, contactin-1 and complement activation in anti-MAG IgM paraprotein-related peripheral neuropathy. <i>Journal of Neurology</i> , 2022, 269, 3700-3705.	1.8	8

#	ARTICLE	IF	CITATIONS
73	Discriminating between Waldenström macroglobulinemia and marginal zone lymphoma using logistic LASSO regression. <i>Leukemia and Lymphoma</i> , 2022, 63, 1070-1079.	0.6	8
74	Radioimmunotherapy in follicular lymphoma: Some like it hot. <i>Transfusion and Apheresis Science</i> , 2011, 44, 173-178.	0.5	7
75	Ixazomib, Rituximab and Dexamethasone (IRD) in Patients with Relapsed or Progressive Waldenstrom's Macroglobulinemia: Results of the Prospective Phase I/II HOVON 124/Ecwm-R2 Trial. <i>Blood</i> , 2019, 134, 344-344.	0.6	7
76	Interim Analysis Of Dose-Escalation Stage Of a Phase 1b Study Evaluating Safety and Pharmacology Of GS-9820, a Second-Generation, Selective, PI3Kd-Inhibitor in Recurrent Lymphoid Malignancies. <i>Blood</i> , 2013, 122, 2881-2881.	0.6	7
77	Phase 2 Study of Carfilzomib, Thalidomide, and Low-Dose Dexamethasone As Induction/Consolidation in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma, the Carthadex Trial. <i>Blood</i> , 2016, 128, 1141-1141.	0.6	7
78	Preliminary results of earlier steroid use with axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL).. <i>Journal of Clinical Oncology</i> , 2019, 37, 7558-7558.	0.8	7
79	Primary therapy and relative survival in patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia: a population-based study in the Netherlands, 1989-2018. <i>British Journal of Haematology</i> , 2022, 196, 660-669.	1.2	7
80	Comparative efficacy of tisagenlecleucel and lisocabtagene maraleucel among adults with relapsed/refractory large B-cell lymphomas: an indirect treatment comparison. <i>Leukemia and Lymphoma</i> , 2022, 63, 845-854.	0.6	6
81	Time trends in primary therapy and relative survival of diffuse large B-cell lymphoma by stage: a nationwide, population-based study in the Netherlands, 1989-2018. <i>Blood Cancer Journal</i> , 2022, 12, 38.	2.8	6
82	Biological and Clinical Implications of Gene-Expression Profiling in Diffuse Large B-Cell Lymphoma: A Proposal for a Targeted BLYM-777 Consortium Panel as Part of a Multilayered Analytical Approach. <i>Cancers</i> , 2022, 14, 1857.	1.7	6
83	Targeting cell adhesion and homing as strategy to cure Waldenström's macroglobulinemia. <i>Best Practice and Research in Clinical Haematology</i> , 2016, 29, 161-168.	0.7	5
84	Rare but Serious: Ibrutinib Induced Liver Failure. <i>HemaSphere</i> , 2019, 3, e307.	1.2	5
85	The impact of prior malignancies on the development of second malignancies and survival in follicular lymphoma: A population-based study. <i>EJHaem</i> , 2020, 1, 489-497.	0.4	5
86	Effective Information Provision About the Side Effects of Treatment for Malignant Lymphoma: Protocol of a Randomized Controlled Trial Using Video Vignettes. <i>JMIR Research Protocols</i> , 2019, 8, e12453.	0.5	5
87	Risk of second primary malignancies in patients with follicular lymphoma: a population-based study in the Netherlands, 1989-2018. <i>Blood Cancer Journal</i> , 2021, 11, 179.	2.8	5
88	Health-related quality of life in cancer immunotherapy: a systematic perspective, using causal loop diagrams. <i>Quality of Life Research</i> , 2022, 31, 2357-2366.	1.5	5
89	How to choose first salvage therapy in Hodgkin lymphoma: traditional chemotherapy vs novel agents. <i>Hematology American Society of Hematology Education Program</i> , 2021, 2021, 240-246.	0.9	5
90	Bendamustine Plus Rituximab for the Treatment of Waldenström Macroglobulinaemia: Patient Outcomes and Impact of Bendamustine Dosing. <i>Blood</i> , 2020, 136, 10-11.	0.6	4

#	ARTICLE	IF	CITATIONS
91	Bortezomib-Based Induction and Maintenance Overcomes the Negative Prognostic Impact of Renal Impairment and del17p in Transplant-Eligible Myeloma Patients: Long Term Results from the Phase III HOVON-65/GMMG-HD4 Study after Median 137 Months Follow up. <i>Blood</i> , 2019, 134, 3308-3308.	0.6	3
92	Combined Inhibition of mTOR and DNA-PK Blocks Survival, Adhesion, Proliferation and Chemoresistance in Primary Chronic Lymphocytic Leukemia (CLL) Cells. <i>Blood</i> , 2014, 124, 1981-1981.	0.6	3
93	Effect of Brentuximab Vedotin Addition to Chemotherapy and Prognostic Factors in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Large Multi-Trial Analysis Based on Individual Patient Data. <i>Blood</i> , 2021, 138, 879-879.	0.6	3
94	T-cell subset composition and functionality in patients with WaldenstrÃ¶m's macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2022, , 1-5.	0.6	3
95	Causes of death of patients with follicular lymphoma in the Netherlands by stage and age groups: a population-based study in the pre- and post-rituximab era. <i>Leukemia</i> , 2022, 36, 1416-1420.	3.3	3
96	HOVON110/ReBeL Study: Results of the Phase I Part of a Randomized Phase I/II Study of Lenalidomide, Rituximab With or Without Bendamustine in Patients With Relapsed/Refractory Follicular Lymphoma. <i>HemaSphere</i> , 2020, 4, e325.	1.2	2
97	Comparative efficacy of tisagenlecleucel (tisa-cel) and lisocabtagene maraleucel (liso-cel) in patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL).. <i>Journal of Clinical Oncology</i> , 2021, 39, 7535-7535.	0.8	2
98	EHA Endorsement of ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up for WaldenstrÃ¶m's Macroglobulinemia. <i>HemaSphere</i> , 2021, 5, e634.	1.2	2
99	Defining the Incidence, Pathology and Clinical Outcomes of Kidney Disease Related to Waldenstrom's Macroglobulinemia and IgM MGUS. <i>Blood</i> , 2015, 126, 3926-3926.	0.6	2
100	Conditional relative survival in WaldenstrÃ¶m's macroglobulinaemia: a population-based study in The Netherlands. <i>British Journal of Haematology</i> , 2021, , .	1.2	2
101	Evaluating Patients' Preferences Regarding Treatment Options for WaldenstrÃ¶m's Macroglobulinemia, a Discrete-Choice-Experiment. <i>Blood</i> , 2021, 138, 835-835.	0.6	2
102	Conditional relative survival among patients with follicular lymphoma: a population-based study in the Netherlands. <i>Blood Cancer Journal</i> , 2021, 11, 12.	2.8	1
103	Conditional relative survival among patients with nodular lymphocyte-predominant Hodgkin lymphoma in the Netherlands. <i>Blood Cancer Journal</i> , 2021, 11, 87.	2.8	1
104	Cost-effectiveness of lenalidomide plus rituximab versus rituximab monotherapy in patients with previously treated follicular lymphoma: a societal view. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1-12.	1.1	1
105	Whimsical (Waldenstrom's Macroglobulinemia Study Involving CArt-wheelL): A Global Patient-Derived Data Registry Capturing Treatment, Quality of Life and COVID-19 Data. <i>Blood</i> , 2020, 136, 30-31.	0.6	1
106	Gene Expression Profiles Are Best Suited To Assess Present Though Not Future Clinical Aggressiveness in Follicular Lymphoma.. <i>Blood</i> , 2004, 104, 698-698.	0.6	1
107	A Phase 1B Study of CC-122 in Combination with Obinutuzumab (GA101) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Indolent Non-Hodgkin Lymphoma. <i>Blood</i> , 2016, 128, 4199-4199.	0.6	1
108	Combined Inhibition of Phosphatidylinositol 3-Kinase (PI3K) Isoform Î± and Î³ By the Pan-Class I PI3K Inhibitor SAR245409 (XL765) in Primary Chronic Lymphocytic Leukemia Cells Blocks Survival, Adhesion and Proliferation. <i>Blood</i> , 2014, 124, 4691-4691.	0.6	1

#	ARTICLE	IF	CITATIONS
109	The Impact of Allogeneic Stem Cell Transplantation As Part of First Line Treatment on Outcome of Patients with Multiple Myeloma Depends on the Method of Analysis. <i>Blood</i> , 2014, 124, 1209-1209.	0.6	1
110	First-Line Treatment and Survival of Stage I(E) Peripheral T-Cell Lymphoma in the Netherlands; A Nationwide Population-Based Cohort Study. <i>Blood</i> , 2021, 138, 1381-1381.	0.6	1
111	Professor Anton Hagenbeek 1948â€“2021: Father of MRD and lymphoma expert. <i>Bone Marrow Transplantation</i> , 2021, 56, 2038-2039.	1.3	0
112	Gene Expression Profiling Can Predict Responsiveness to Chemotherapy in Patients with Transformation of Follicular Lymphoma.. <i>Blood</i> , 2006, 108, 823-823.	0.6	0
113	CMV-Associated Expansion of CD8+CD45RA+CD27âˆ™ T-Cells in Patients with B-Cell Malignancies.. <i>Blood</i> , 2007, 110, 3592-3592.	0.6	0
114	In Vivo Tumor Dynamic Studies in Stable CLL Show an Association between CLL Turnover Rates and IgVH Mutational Status and Provide Evidence That the Bone Marrow Is Not a Major Site of Neoplastic Cell Generation.. <i>Blood</i> , 2007, 110, 1128-1128.	0.6	0
115	Genetic Associations with Therapy Response in the HOVON-65/GMMG-HD4 Trial in Patients with Multiple Myeloma.. <i>Blood</i> , 2009, 114, 1790-1790.	0.6	0
116	High Incidence of Peripheral Blood Plasmacytosis In Patients with Dengue Virus Infection: a Prospective Study. <i>Blood</i> , 2010, 116, 2772-2772.	0.6	0
117	Phase I/II Trial of Weekly Escalated Dose Bortezomib Combined with Lenalidomide and Dexamethasone in Patients in First Relapse or Primary Refractory Disease after First Line Therapy for Multiple Myeloma. <i>Blood</i> , 2014, 124, 4735-4735.	0.6	0
118	Tumor Specific Glycosylated CD43 Is a Novel and Highly Specific Target for Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Blood</i> , 2016, 128, 1646-1646.	0.6	0
119	Global WaldenstrÃ¶m's Macroglobulinemia Patient-Derived Data Registry, Whimsical, Highlights Real-World Treatment Outcomes and COVID-19 Data. <i>Blood</i> , 2021, 138, 1343-1343.	0.6	0